PEEL Therapeutics
Engineering molecules found in nature into medicines for cancer and inflammatory diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $9.0m | Seed |
| Total Funding | 000k | ||
Related Content
Peel Therapeutics is a clinical stage biotech company focused on translating evolutionary superabilities into transformative medicines. The company leverages its expertise in life sciences to identify and harness the therapeutic potential of evolutionary outliers—organisms and molecules that have naturally evolved to circumvent diseases. Peel Therapeutics operates in the biotechnology sector, primarily serving patients with severe health conditions, including children and teenagers. The business model revolves around research and development (R&D) to create innovative therapies, which are then brought to market through clinical trials and partnerships with pharmaceutical companies. Revenue is generated through the commercialization of these therapies and potential collaborations with other biotech firms. The company is headquartered in Salt Lake City, Utah, with a significant presence in Haifa, Israel, and employs a diverse team from various sectors including industry, academia, and clinical medicine.
Keywords: biotech, clinical stage, evolutionary superabilities, transformative medicines, therapeutic potential, life sciences, severe health conditions, R&D, clinical trials, pharmaceutical partnerships.